Karyopharm's Selinexor Shows Progression-Free Survival of 27.4 Months In Endometrial Cancer With Certain Mutation
Portfolio Pulse from Vandana Singh
Karyopharm Therapeutics Inc announced updated exploratory subgroup analyses from the SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer. The analysis showed a promising efficacy signal with a median progression-free survival (PFS) of 27.4 months for selinexor-treated patients. The data provides further rationale for the ongoing pivotal Phase 3 study of selinexor as maintenance therapy. Karyopharm is currently enrolling patients in this study. However, KPTI shares are down 4.09% at $1.53.
July 26, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Karyopharm's selinexor shows promising results in endometrial cancer study, but the company's shares are down 4.09%.
The promising results from the SIENDO study could potentially boost Karyopharm's reputation and market position in the long term. However, the immediate market reaction has been negative, with the company's shares down 4.09%. This could be due to various factors, including market volatility or investor sentiment not fully aligning with the study results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100